The search for clinical outcome predictors for schizophrenia is as old as the field of
psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors …

In March 2005, the Remission in Schizophrenia Working Group (RSWG) proposed a
consensus definition of symptomatic remission in schizophrenia and developed specific …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

The variability in the response to antipsychotic medication in schizophrenia may reflect
between-patient differences in neurobiology. Recent cross-sectional neuroimaging studies …

Current guidelines for patients with schizophrenia spectrum disease do not take sex
differences into account, which may result in inappropriate sex-specific treatment. In the …

The RSWG remission criteria are easy to apply and define an achievable and desirable
treatment goal. Measures of social and occupational functional outcome, quality of life and …

The integrity of brain white matter connections is central to a patient's ability to respond to
pharmacological interventions. This study tested this hypothesis using a specific measure of …

Background: Clinical and functional outcome improvement in psychotic disorders is a
challenge for the investigators. Recent advances offered opportunities for ameliorating the …

Schizophrenia has long been hypothesized to result from a disconnection syndrome due to
a disruption of the association fibers of the brain. However, only with the advent of in vivo …

Abstract In 2005, the Remission in Schizophrenia Working Group published consensus
criteria to define remission. These criteria have been widely accepted and utilized and have …